Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P48735
UPID:
IDHP_HUMAN
Alternative names:
ICD-M; IDP; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase
Alternative UPACC:
P48735; B2R6L6; B4DFL2; Q96GT3
Background:
Isocitrate dehydrogenase [NADP], mitochondrial (IDH), with alternative names such as ICD-M and NADP(+)-specific ICDH, plays a pivotal role in intermediary metabolism and energy production. It is known to closely associate or interact with the pyruvate dehydrogenase complex, highlighting its integral role in cellular metabolic pathways.
Therapeutic significance:
IDH's involvement in D-2-hydroxyglutaric aciduria 2, characterized by developmental delay and epilepsy, and its role in glioma pathogenesis, underscores its therapeutic potential. Targeting IDH mutations could lead to innovative treatments for these conditions, emphasizing the importance of understanding its biological functions.